This site is intended for health professionals only

Published on 29 June 2015

Share this story:
Twitter
LinkedIn

Clinigen Group’s £225m acquisition of Idis supported by £106m in funding from Santander, RBS and HSBC

 Burton-on-Trent based Clinigen Group plc., the specialty global pharmaceutical company, has acquired Idis Group Holdings Ltd to create the market leader in the ethical unlicenced supply of medicines following £106 million in funding from Santander Corporate & Commercial, Royal Bank of Scotland and HSBC. Idis has been acquired for an enterprise value of £225 million.

 Burton-on-Trent based Clinigen Group plc., the specialty global pharmaceutical company, has acquired Idis Group Holdings Ltd to create the market leader in the ethical unlicenced supply of medicines following £106 million in funding from Santander Corporate & Commercial, Royal Bank of Scotland and HSBC. Idis has been acquired for an enterprise value of £225 million.

The Clinigen Group is dedicated to delivering ‘the right drug, to the right patient at the right time’. Through its complementary business units Clinigen supplies clinical trial, licensed and ethical unlicenced critical and life-saving drugs, and serves patients, the medical community and the healthcare industry. Established for 25 years, Idis supplies ethical unlicenced medicines predominantly on an exclusive basis through managed access programmes and on-demand through its general access division.

Peter George, Chief Executive Officer of Clinigen Group, said: “Our acquisition of Idis makes us the market leader in the $5+ billion ethical unlicenced medicine supply sector and strengthens our leading position in the $2 billion clinical trial supply market. The acquisition accelerates our growth and gives us a much better balanced portfolio of businesses, whilst extending our unique business model.

Joe Duane, Relationship Director – Large Corporates, Santander Corporate & Commercial, said: “The global ethical unlicenced supply market represents a significant growth opportunity for Clinigen. As a market leader, the firm will look to shape and define the fast growing market, and we are delighted to be able to support the group in this endeavour.

Steve North, Relationship Director – Large Corporates, HSBC said: “The acquisition of Idis is strategically compelling and a complementary fit for Clinigen’s unique business model, creating the market leader in its field. HSBC is proud to support the group as it enters its next chapter of growth.

Steve Simpson, Director – Structured Finance, RBS Commercial & Private Banking, said:“RBS have held a relationship with Clinigen for many years and we are delighted to welcome both HSBC and Santander into the banking arrangement to further support Clinigen’s growth.



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn